|
|
Volumn 109, Issue 8, 2013, Pages 2051-2057
|
|
Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009-2010)
a
a
a
a
a
a
a
a
a
|
|
Author keywords
clinical trial costs; cost attribution; excess treatment costs; research costs; treatment cost savings; treatment costs
|
|
Indexed keywords
AFLIBERCEPT;
ANASTROZOLE;
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CAPECITABINE;
CARBOPLATIN;
CETUXIMAB;
CISPLATIN;
DOCETAXEL;
DOXORUBICIN;
ELESCLOMOL;
EVEROLIMUS;
EXEMESTANE;
FLUOROURACIL;
FULVESTRANT;
INTERFERON;
LETROZOLE;
PACLITAXEL;
PANITUMUMAB;
PREDNISOLONE;
RIDAFOROLIMUS;
SORAFENIB;
STREPTOZOCIN;
SUNITINIB;
TASISULAM;
TEMOZOLOMIDE;
TEMSIROLIMUS;
TRASTUZUMAB;
UNINDEXED DRUG;
ZIBOTENTAN;
ARTICLE;
BREAST CANCER;
CANCER PATIENT;
CHEMORADIOTHERAPY;
CLINICAL TRIAL (TOPIC);
COLORECTAL CANCER;
COST BENEFIT ANALYSIS;
COST CONTROL;
DRUG COST;
ESOPHAGUS CANCER;
GLIOMA;
GYNECOLOGIC CANCER;
HEALTH CARE COST;
HEALTH CARE QUALITY;
HUMAN;
KIDNEY CANCER;
LIVER CELL CARCINOMA;
LOW DRUG DOSE;
LUNG CANCER;
MELANOMA;
MULTIPLE CYCLE TREATMENT;
NEUROENDOCRINE TUMOR;
PANCREAS CANCER;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROSTATE CANCER;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RHABDOMYOSARCOMA;
SARCOMA;
STOMACH CANCER;
STUDY DESIGN;
TREATMENT DURATION;
UNITED KINGDOM;
BIOMEDICAL RESEARCH;
CLINICAL TRIALS AS TOPIC;
CLINICAL TRIALS, PHASE II AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
GREAT BRITAIN;
HEALTH CARE COSTS;
HUMANS;
MEDICAL ONCOLOGY;
NEOPLASMS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RETROSPECTIVE STUDIES;
|
|
EID: 84885945713
PISSN: 00070920
EISSN: 15321827
Source Type: Journal
DOI: 10.1038/bjc.2013.495 Document Type: Article |
|
Times cited : (24)
|
|
References (13)
|
